CDD to make Eli Lilly models available in CDD Vault 

Collaborative Drug Discovery (CDD) has announced an agreement with Eli Lilly to make Lilly’s AI/ML models available in CDD Vault. 

The models will come from Lilly TuneLab, the platform created by Lilly to accelerate biotech innovation by enabling participating companies to access models trained on decades of Lilly’s proprietary research data. 

Through this agreement, biotech companies that use CDD Vault will be able to utilise select Lilly predictive models within their natural scientific workflows. 

This agreement paves the way for the planned integration of Lilly TuneLab in both the core and AI modules within CDD Vault for biotech companies that opt in to the programme. 

“By integrating TuneLab directly into CDD Vault, we are advancing CDD’s core vision to enable collaboration across drug discovery teams and organisations,” said Dr Barry Bunin, CDD Chief Executive Officer and President. 

“We believe that solving the most complex challenges in drug discovery will depend on innovative collaboration models that provide broad access to research data and empower chemists and biologists to make informed, data-driven decisions. 

“TuneLab’s ADMET models will fit in our trusted secure CDD Vault software environment in natural workflows for experimental and computational scientists and with our growing CDD Vault ecosystem of biopharmaceutical companies.” 

The post CDD to make Eli Lilly models available in CDD Vault  appeared first on Drug Discovery World (DDW).